• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of diabetes and its complications >A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.
【24h】

A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.

机译：赖脯胰岛素和通过连续皮下胰岛素输注泵给药的普通人胰岛素缓冲液的比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study compared glycemic control achieved with insulin lispro or buffered regular human insulin in patients with Type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) using an external insulin pump. In this 24-week multicenter, randomized, two-way crossover, open-label trial, 58 patients on CSII with adequate glycemic control received either insulin lispro or buffered regular human insulin for 12 weeks, followed by the alternate treatment for another 12 weeks. Efficacy and safety measures included hemoglobin A(1c) (HbA(1c)) at baseline and endpoint, home blood glucose monitoring, hypoglycemia, and frequency of pump catheter occlusion. Patients consumed a standard test meal on three occasions, with determinations of fasting, 1- and 2-h postprandial glucose values. Insulin lispro use was associated with a significantly lower HbA(1c) than was buffered regular human insulin (7.41+/-0.97 vs. 7.65+/-0.85 mmol/l; P=.004). Fasting serum glucose values before the test meal were similar between the two therapies. The 1-h (11.16+/-4.29 vs. 13.20+/-4.68 mmol/l; P=.012) and 2-h (9.64+/-4.10 vs. 12.53+/-4.64 mmol/l; P=.001) postprandial glucose concentrations were significantly lower during treatment with insulin lispro. No differences between treatments were observed in basal or bolus insulin doses, weight gain, or the incidence and rate of hypoglycemia, hyperglycemia, or pump occlusions. When used in external pumps, insulin lispro provides better glycemic control than buffered regular human insulin with a similar adverse event profile.
机译：这项研究比较了使用赖脯胰岛素或常规人类胰岛素缓冲液对使用外部胰岛素泵连续皮下胰岛素输注（CSII）治疗的1型糖尿病患者的血糖控制。在这项为期24周的多中心，随机，双向，开放标签试验中，58名接受了适当血糖控制的CSII患者接受了赖脯胰岛素或普通人胰岛素缓冲液治疗12周，然后再交替治疗12周。有效性和安全性措施包括基线和终点处的血红蛋白A（1c）（HbA（1c）），家庭血糖监测，低血糖和泵导管阻塞的频率。患者分三次进食标准测试餐，测定空腹，餐后1和2小时的血糖值。赖脯胰岛素的使用与HbA（1c）显着低于缓冲的普通人胰岛素（7.41 +/- 0.97 vs.7.65 +/- 0.85 mmol / l; P = .004）。两种疗法之间，试验餐前的空腹血糖值相似。 1-h（11.16 +/- 4.29 vs. 13.20 +/- 4.68 mmol / l; P = .012）和2-h（9.64 +/- 4.10 vs. 12.53 +/- 4.64 mmol / l; P =。 001）赖脯胰岛素治疗期间餐后血糖浓度显着降低。在基础或推注胰岛素剂量，体重增加或低血糖，高血糖或泵浦性闭塞的发生率和发生率方面，未观察到治疗之间的差异。当用于外部泵时，赖脯胰岛素比具有相似不良事件特征的常规人胰岛素缓冲液提供更好的血糖控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号